Page 24 of 28
We describe a 72-year-old man, who had been suffered from Henoch-Schönlein purpura (HSP) several times, presented with hematoproteinuria with granular cast, and general lymphadenopathy. The immunological exami...
This case reports the unique association of eosinophilic gastrointestinal disease with eosinophilic bronchitis, asthma and chronic rhinosinusitis and some features of lymphocytic hypereosinophilic syndrome, de...
H1N1 is responsible for the first influenza pandemic in 41 years. In the fall of 2009, an H1N1 vaccine became available in Canada with the hopes of reducing the overall effect of the pandemic. The purpose of t...
This document provides healthcare practitioners with information regarding the management of acute rhinosinusitis (ARS) and chronic rhinosinusitis (CRS) to enable them to better meet the needs of this patient ...
The 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema was published earlier this year in this Journal (Bowen et al. Allergy, Asthma & Clinical Immunology 20...
This article is part of a Supplement: Volume 6 Supplement 2
This article is part of a Supplement: Volume 6 Supplement 2
Food allergy can cause life threatening reactions. Currently, patients with severe food allergy are advised to avoid foods which provoke allergic reactions. This has become increasingly difficult as food prote...
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
This article is part of a Supplement: Volume 6 Supplement 4
Omalizumab has demonstrated efficacy among patients with moderate to severe persistent allergic asthma, whose symptoms are inadequately controlled with other controller agents. This therapy is generally well t...
Prevalence of asthma and allergies in top athletes is high. However, most previous studies did not include a general population comparison group. We aimed to compare the prevalence of asthma, allergies and med...
Research has shown that the long term management of food allergy is suboptimal. Our study aims to provide direction for improvement, by evaluating food allergy management from the perspective of, food allergic...
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
This article is part of a Supplement: Volume 6 Supplement 3
The official journal of CSACI
2022 Citation Impact
2.7 - 2-year Impact Factor
3.4 - 5-year Impact Factor
0.989 - SNIP (Source Normalized Impact per Paper)
0.634 - SJR (SCImago Journal Rank)
2022 Speed
16 days submission to first editorial decision for all manuscripts (Median)
133 days submission to accept (Median)
2022 Usage
1,447,234 downloads
5,769 Altmetric mentions